Company Analysis Protagenic Therapeutics, Inc.
1. Summary
Advantages
- The stock's return over the last year (468%) is higher than the sector average (-46.04%).
- Current debt level 17.59% is below 100% and has decreased over 5 years from 33.17%.
Disadvantages
- Price (3.41 $) is higher than fair price (2.76 $)
- Dividends (0%) are below the sector average (0.6831%).
- The company's current efficiency (ROE=-236.06%) is lower than the sector average (ROE=18.49%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
Protagenic Therapeutics, Inc. | Technology | Index | |
---|---|---|---|
7 days | -2.2% | -23.2% | 1.2% |
90 days | 1176.4% | -48.8% | 21.7% |
1 year | 468% | -46% | 21.8% |
PTIX vs Sector: Protagenic Therapeutics, Inc. has outperformed the "Technology" sector by 514.04% over the past year.
PTIX vs Market: Protagenic Therapeutics, Inc. has outperformed the market by 446.24% over the past year.
Highly volatile price: PTIX is significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical deviations of more than +/- 15% per week.
Long period: PTIX with weekly volatility of 9% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (3.41 $) is higher than the fair price (2.76 $).
Price is higher than fair: The current price (3.41 $) is 19.1% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (199.46).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (90.03).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.37) is lower than that of the sector as a whole (10.29).
P/BV vs Market: The company's P/BV (2.37) is lower than that of the market as a whole (9.39).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (8.59).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (10.12).
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.1027) is lower than that of the sector as a whole (10.95).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.1027) is lower than that of the market as a whole (50.91).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 16.84% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (16.84%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-10.38%).
5.4. ROE
ROE vs Sector: The company's ROE (-236.06%) is lower than that of the sector as a whole (18.49%).
ROE vs Market: The company's ROE (-236.06%) is lower than that of the market as a whole (11.64%).
5.5. ROA
ROA vs Sector: The company's ROA (-175.99%) is lower than that of the sector as a whole (9.96%).
ROA vs Market: The company's ROA (-175.99%) is lower than that of the market as a whole (6.89%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-100.07%) is lower than that of the sector as a whole (13.81%).
ROIC vs Market: The company's ROIC (-100.07%) is lower than that of the market as a whole (11.08%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.6831%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription